# ANGO Stock: AngioDynamics Jumped 11% — Because Medicare Said Yes

Page: https://stenobird.com/podcast/charged-alpha-stock-encyclopedia-7819792/ango-stock-angiodynamics-jumped-11-because-medicare-said-yes
Text version: https://stenobird.com/podcast/charged-alpha-stock-encyclopedia-7819792/ango-stock-angiodynamics-jumped-11-because-medicare-said-yes.md
Podcast: [Charged Alpha Stock Encyclopedia](https://stenobird.com/podcast/charged-alpha-stock-encyclopedia-7819792)
Published: 2026-07-15T16:01:33+00:00
Episode link: https://chargedalpha.podbean.com/e/ango-stock-angiodynamics-jumped-11-%e2%80%94-because-medicare-said-yes/
Audio file: https://mcdn.podbean.com/mf/web/vp8ap1hm5a4qb3xb/audio_x.mp3
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/charged-alpha-stock-encyclopedia-7819792/episodes/ango-stock-angiodynamics-jumped-11-because-medicare-said-yes
Duration seconds: 679

## Resource

AngioDynamics (ANGO) Q4 FY2026 — AngioDynamics beat on its fiscal Q4 (revenue $86.6M, +8%; adjusted loss of $0.07, 4 cents better than feared), grew full-year Med Tech 18%, and guided FY27 revenue above consensus. The stock jumped ~11% to a 52-week high, led by NanoKnife (+64.5%) as Medicare coverage for its prostate-ablation therapy went live July 5. AngioDynamics quietly reinvented itself: it sold its low-margin legacy lines and rebuilt around two growth platforms, and the star is NanoKnife — which destroys prostate tumors with electricity (a focal therapy that spares patients the incontinence/impotence risks of surgery or radiation). The catalyst just completed: FDA clearance (2024), billing codes live (Jan 1), and Medicare coverage effective July 5. NanoKnife grew 64.5% with capital placements up 132% — every machine placed is a razor that sells disposable probes for years. At ~1.7x sales, debt-free, the valuation is reasonable and the catalyst is only days old. But it just popped 11% to a 52-week high and more than half the company barely grows. A SPECULATIVE BUY — real catalyst, mind the entry. Fair value ~$18. THE CALL: SPECULATIVE BUY (3/5, REAL CATALYST, MIND THE ENTRY) — base-case value ~$18 vs ~$14.43 today. What to watch: disposable-probe (utilization) revenue accelerating in the quarters after the 132% jump in machine placements and the July 5 Medicare coverage, the Med Device drag on blended growth, and the path to GAAP profitability Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/charged-alpha-stock-encyclopedia-7819792/episodes/ango-stock-angiodynamics-jumped-11-because-medicare-said-yes/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/charged-alpha-stock-encyclopedia-7819792/ango-stock-angiodynamics-jumped-11-because-medicare-said-yes.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.